Century Therapeutics Inc (IPSC) Stock Price, Quote & News

Company Profile

Century Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed and refractory B-cell lymphoma. The company is also involved in the development of CNTY...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 817 5790

Website: www.centurytx.com

Address:

25 North 38th Street, 11th Floor, Philadelphia, United States

valueforme Aug. 16 at 9:07 PM

$IPSC After July RIF they will likely be burning around 16-18M per quarter I think. So, by the end of 2025 they will have around 120M which is $1.40 of cash per share. I don't think that CTNY-101 shows anything ground breaking. CNTY-308 looks way more interesting, but pretty far from clinic. So, after PO potential CTNY-101 fiasco selling the tech with minimal positive EV or liquidating would be pretty logical.

0 · Reply

CelestialIronMan Aug. 15 at 6:06 AM

$IPSC just pack up and go squat at $SANA while company, I’ll help you move!

0 · Reply

None_ Aug. 15 at 1:45 AM

$IPSC https://www.globenewswire.com/news-release/2025/08/14/3133827/0/en/Century-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

0 · Reply

valueforme Aug. 14 at 9:07 PM

$IPSC Tang, throw them a bone https://www.biospace.com/business/tang-capitals-concentra-on-buyout-binge-with-plenty-of-biotech-fodder

0 · Reply

valueforme Aug. 14 at 8:18 PM

$IPSC "Cash runway extended into fourth quarter 2027" . Good

1 · Reply

valueforme Aug. 14 at 4:21 PM

$IPSC "Contact us" page on their web site

1 · Reply

valueforme Aug. 14 at 3:49 PM

$IPSC "The Company has 180 days, or until August 25, 2025, to comply with Rule 5450(a)(1) by maintaining a closing bid price of at least $1.00 per share for at least 10 consecutive business days, and the Company must otherwise satisfy the Nasdaq Global Select Market’s requirements for listing. " 2 weeks to do something. Board of directors is full of decorated veterans. I hope they do understand that it's time to do something here.

0 · Reply

valueforme Aug. 14 at 3:35 PM

$IPSC Dug a bit more, yep, it looks like a liquidation or reverse merger play with a decent amount of cash in the coffers + manufacturing facility as an asset. Bought today

0 · Reply

valueforme Aug. 14 at 1:55 AM

$IPSC Interesting. Will these clowns report tomorrow or not? How much cash is remaining? They are not running like some other beaten down cell therapy names. Can it be a liquidation play?

0 · Reply

biochirp Aug. 13 at 1:44 PM

$IPSC please to god shut down this shii dont work

0 · Reply

Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

May 28, 2025, 4:01 PM EDT - 2 months ago

Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress

May 15, 2025, 4:01 PM EDT - 3 months ago

Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:30 PM EDT - 3 months ago

Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting

Mar 19, 2025, 4:01 PM EDT - 5 months ago

Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Nov 26, 2024, 7:00 AM EST - 9 months ago

Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 5, 2024, 9:05 AM EST - 10 months ago

Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 4, 2024, 7:00 AM EST - 10 months ago

Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Sep 26, 2024, 7:00 AM EDT - 11 months ago

Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer

Aug 8, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Jun 20, 2024, 11:07 AM EDT - 1 year ago

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 3, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Apr 23, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics

Apr 8, 2024, 4:05 PM EDT - 1 year ago

Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 19, 2024, 7:00 AM EDT - 1 year ago

Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Mar 14, 2024, 7:30 AM EDT - 1 year ago

Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates

Mar 5, 2024, 6:03 PM EST - 1 year ago

Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Feb 1, 2024, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Dec 9, 2023, 12:00 PM EST - 1 year ago

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

$Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus$

Dec 6, 2023, 7:30 AM EST - 1 year ago

Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus

Nov 21, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference

Nov 9, 2023, 7:01 AM EST - 1 year ago

Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 9, 2023, 7:00 AM EST - 1 year ago

Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases

Sep 26, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference

Aug 9, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates

May 11, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 17, 2023, 7:00 AM EDT - 2 years ago

Century Therapeutics to Present at Chardan's 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit

Apr 12, 2023, 8:30 AM EDT - 2 years ago

Century Therapeutics Announces Leadership Changes

Mar 16, 2023, 7:30 AM EDT - 2 years ago

Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates

Mar 15, 2023, 4:01 PM EDT - 2 years ago

Century Therapeutics to Present at the AACR Annual Meeting 2023

Feb 21, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at Upcoming Investor Conferences

$Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas$

Feb 8, 2023, 7:30 AM EST - 2 years ago

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE TECH

Jan 10, 2023, 7:33 AM EST - 2 years ago

Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)

FATE THRD VERA

Jan 9, 2023, 9:06 PM EST - 2 years ago

Century Therapeutics closes its Seattle hub amid wider cuts, departure of R&D head

Jan 5, 2023, 4:01 PM EST - 2 years ago

Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026

Jan 4, 2023, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 22, 2022, 7:00 AM EST - 2 years ago

Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 11, 2022, 7:00 AM EST - 3 years ago

Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates

Nov 10, 2022, 7:30 AM EST - 3 years ago

Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 2, 2022, 7:05 AM EDT - 3 years ago

Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Century Therapeutics to Present at the SITC 37th Annual Meeting

Oct 3, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors

Sep 26, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at Chardan's 6th Annual Genetic Medicines Conference

Sep 6, 2022, 7:00 AM EDT - 3 years ago

Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 25, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Receives Study May Proceed Notification from FDA for CNTY-101, the First Allogeneic Cell Therapy Product Candidate Engineered to Overcome Three Major Pathways of Host vs Graft Rejection

Aug 11, 2022, 7:30 AM EDT - 3 years ago

Century Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates

valueforme Aug. 16 at 9:07 PM

0 · Reply

CelestialIronMan Aug. 15 at 6:06 AM

$IPSC just pack up and go squat at $SANA while company, I’ll help you move!

0 · Reply

None_ Aug. 15 at 1:45 AM

$IPSC https://www.globenewswire.com/news-release/2025/08/14/3133827/0/en/Century-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

0 · Reply

valueforme Aug. 14 at 9:07 PM

$IPSC Tang, throw them a bone https://www.biospace.com/business/tang-capitals-concentra-on-buyout-binge-with-plenty-of-biotech-fodder

0 · Reply

valueforme Aug. 14 at 8:18 PM

$IPSC "Cash runway extended into fourth quarter 2027" . Good

1 · Reply

valueforme Aug. 14 at 4:21 PM

$IPSC "Contact us" page on their web site

1 · Reply

valueforme Aug. 14 at 3:49 PM

0 · Reply

valueforme Aug. 14 at 3:35 PM

$IPSC Dug a bit more, yep, it looks like a liquidation or reverse merger play with a decent amount of cash in the coffers + manufacturing facility as an asset. Bought today

0 · Reply

valueforme Aug. 14 at 1:55 AM

$IPSC Interesting. Will these clowns report tomorrow or not? How much cash is remaining? They are not running like some other beaten down cell therapy names. Can it be a liquidation play?

0 · Reply

biochirp Aug. 13 at 1:44 PM

$IPSC please to god shut down this shii dont work

0 · Reply

biochirp Aug. 8 at 5:26 PM

$IPSC SHUT IT DOWN LOL

1 · Reply

biochirp Jul. 31 at 6:42 PM

$IPSC

0 · Reply

biochirp Jul. 30 at 1:43 PM

$IPSC why won’t this shitco shutdown already

1 · Reply

NVDAMillionaire Jul. 24 at 11:58 PM

$IPSC Excellent article that nails exactly where IPSC stands right now. So if you want to update your IPSC knowledge or get acquainted with IPSC, this is a must read. https://beyondspx.com/article/unpacking-century-therapeutics-strategic-shift-and-cash-runway-post-bmy-ipsc

0 · Reply